SCHEDULE 13G/A: Vestal Point Capital and Ryan Wilder Affirm 8.9% Stake in uniQure N.V.

Vestal Point Capital, LP and Ryan Wilder have filed an amendment to their Schedule 13G, confirming their beneficial ownership of 8.9% of uniQure N.V.'s ordinary shares as of March 31, 2025.

Summary

• Vestal Point Capital, LP, an investment manager, and Mr. Ryan Wilder, its Chief Investment Officer and Managing Partner, are the reporting persons for this Schedule 13G Amendment No. 3.
• The filing pertains to their beneficial ownership of Ordinary Shares, par value 0.05 euro per share, of uniQure N.V.
• As of March 31, 2025, the reporting persons collectively beneficially own 4,792,572 Ordinary Shares.
• This ownership represents 8.9% of uniQure N.V.'s outstanding Ordinary Shares.
• The percentage is calculated based on 54,076,880 Ordinary Shares outstanding as of February 24, 2025, as reported in uniQure N.V.'s Annual Report on Form 10-K filed on February 27, 2025.
• The shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of uniQure N.V.

Sentiment

Score: 5

Explanation: The document is a factual regulatory filing (Schedule 13G) reporting beneficial ownership, which inherently carries a neutral sentiment as it does not discuss company performance, strategy, or financial results. It simply confirms a continued significant stake.

Positives

• The continued significant beneficial ownership by Vestal Point Capital, LP and Ryan Wilder, representing 8.9% of the company, indicates a sustained investment and potential confidence in uniQure N.V.

Future Outlook

This Schedule 13G filing is a disclosure of beneficial ownership and does not contain any forward-looking statements or guidance regarding uniQure N.V.'s future performance or outlook.

Industry Context

This filing is a routine regulatory disclosure of beneficial ownership by an investment firm in a biotechnology company. It does not provide specific insights into broader industry trends or competitive landscape, but rather confirms a significant, stable institutional investment in uniQure N.V.

Stakeholder Impact

• For shareholders, the filing indicates that a significant institutional investor, Vestal Point Capital, LP, and its principal, Ryan Wilder, maintain a substantial stake in uniQure N.V., which could be interpreted as a sign of continued investor confidence.

Key Dates

Keywords

uniQure N.V., Vestal Point Capital, Ryan Wilder, Schedule 13G, Beneficial Ownership, Ordinary Shares, SEC Filing, Investment Management, Biotechnology